Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate
Authors
Keywords
T-DM1, Trastuzumab emtansine, HER2, Biliary tract cancer
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-18
DOI
10.1007/s00280-019-03768-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
- (2017) Yoriko Yamashita-Kashima et al. Oncology Letters
- HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
- (2016) Salvatore Galdy et al. CANCER AND METASTASIS REVIEWS
- Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection
- (2016) Yulong Li et al. Diagnostic Pathology
- Therapeutic implication of HER2 in advanced biliary tract cancer
- (2016) Ah-Rong Nam et al. Oncotarget
- Biliary Tract Cancers: Understudied and Poorly Understood
- (2015) Emily Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
- (2015) Tetsutaro Hayashi et al. JOURNAL OF UROLOGY
- Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization
- (2014) Yoriko Yamashita-Kashima et al. Gastric Cancer
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
- (2014) Sun Kim et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab
- (2014) Toru Kawamoto et al. JOURNAL OF GASTROENTEROLOGY
- Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
- (2014) Daniele Cretella et al. Molecular Cancer
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
- (2013) YORIKO YAMASHITA-KASHIMA et al. ONCOLOGY REPORTS
- A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
- (2012) Muralidhar Beeram et al. CANCER
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
- (2012) M. Terashima et al. CLINICAL CANCER RESEARCH
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?
- (2012) H. Wong et al. ONCOLOGIST
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
- (2011) Stephen Lee et al. HISTOPATHOLOGY
- Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
- (2011) Terence C. Chua et al. INTERNATIONAL JOURNAL OF CANCER
- Targeted Therapy for Biliary Tract Cancer
- (2011) Junji Furuse et al. Cancers
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now